Key clinical point: Protein and microRNA expression levels correlated with improved survival on regorafenib among patients with sorafenib-pretreated hepatocellular carcinoma.
Major finding: Among 266 proteins tested, decreased levels of 5 correlated with significantly longer overall survival on regorafenib therapy.
Study details: Preplanned retrospective analysis of plasma and tumor samples from participants in the phase 3 RESOURCE trial.
Disclosures: Bayer funded the study. Dr. Teufel and three coinvestigators are Bayer employees. Dr. Teufel and two coinvestigators own stock in Bayer. Three other coinvestigators disclosed ties to Bayer and other pharmaceutical companies.
Teufel M et al. Gastroenterology. 2019 Jan 30..